Immune Pharmaceuticals Announces the launch of REMAIN (TM) , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia
February 21, 2017
Ceplene Currently Approved in Europe and IsraelREMAIN(TM) to be a pivotal study for US approval NEW YORK, Feb. 17, 2017 /PRNewswire/ — Immune Pharmaceuticals Inc. (Nasdaq: IMNP), will announce on Monday, February 20th, 2017 at the Acute Leukemia XVI symposium in Munich, Germany that it will be launching REMAIN ™, an international Overall Survival clinical study…
Search
RECENT PRESS RELEASES
Related Post
